Abbonarsi

EMERGEncy versus delayed coronary angiogram in survivors of out-of-hospital cardiac arrest with no obvious non-cardiac cause of arrest: Design of the EMERGE trial - 17/03/20

Doi : 10.1016/j.ahj.2020.01.006 
Caroline Hauw-Berlemont, MD a, Lionel Lamhaut, MD, PhD b, Jean-Luc Diehl, MD a, c, Christophe Andreotti, MD d, Olivier Varenne, MD, PhD e, Pierre Leroux, MD f, Jean-Baptiste Lascarrou, MD g, Patrice Guerin, MD, PhD h, Thomas Loeb, MD i, Eric Roupie, MD, PhD j, Cédric Daubin, MD k, Farzin Beygui, MD, PhD l, Aurélie Vilfaillot, MS m, Sophie Glippa m, Juliette Djadi-Prat, MD m, Gilles Chatellier, MD, PhD m, Alain Cariou, MD, PhD n, Christian Spaulding, MD, PhD o,

for the EMERGE investigators

a Medical Intensive Care Unit, European Hospital Georges Pompidou, Assitance Publique-Hôpitaux de Paris, Paris Descartes University, Paris, France 
b Paris Descartes University, Sorbonne Paris Cité-Medical School, Paris, France; Service d'Aide Médicale d'Urgence 75, Necker Hospital (APHP), Paris, France; INSERM U970 (team 4); Paris Cardiovascular Research Centre, Paris, France 
c INSERM UMR-S1140, Paris University, Paris, France 
d Service Mobile d'Urgence et de Réanimation – Emergency Department Cochin - Hôtel Dieu, Assistance Publique- Hôpitaux de Paris, Cochin Hospital, Paris, France 
e Interventional Cardiology, Cardiology Department, Groupe Hospitalier Cochin-Saint Vincent de Paul-Hôtel Dieu, Cochin Hospital, Assistance Publique- Hôpitaux de Paris, Paris, France 
f Service d'Aide Médicale d'Urgence (SAMU) 44, University Hospital of Nantes, Nantes, France 
g Medical Intensive Care Unit, University Hospital of Nantes, Nantes, France 
h Unité d'hémodynamique, L'institut du thorax. University Hospital of Nantes, Nantes, France 
i Service d'Aide Médicale d'Urgence (SAMU) 92, Hôpitaux Universitaires Paris-Saclay, Site Raymond Poincaré, Garches, France 
j Service d'Aide Médicale d'Urgence (SAMU) 14, University Hospital of Caen, Caen, France 
k Medical Intensive Care Unit, University Hospital of Caen, Caen, France 
l Cardiology Department, University Hospital of Caen, Caen, France 
m INSERM CIC1418 and Département d'Informatique, Biostatistique et Santé publique, European Hospital Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France 
n Medical Intensive Care Unit, Cochin Hospital, Assistance Publique- Hôpitaux de Paris, Centre – Université de Paris, Medical School, Paris, France 
o Cardiology Department, European Hospital Georges Pompidou, Assistance Publique- Hôpitaux de Paris, Paris Descartes University, Sudden Cardiac Death Expert Center, INSERM U 971, Paris, France 

Reprint requests: Pr. Christian Spaulding, MD, PhD, Cardiology Department, European Hospital Georges Pompidou, Assistance Publique- Hôpitaux de Paris, Paris Descartes University, Sudden Cardiac Death Expert Center, INSERM U 971, Paris, 75015, France.Cardiology Department, European Hospital Georges Pompidou, Assistance Publique- Hôpitaux de Paris, Paris Descartes University, Sudden Cardiac Death Expert Center, INSERM U 971Paris75015France

Abstract

Background

In adults, the most common cause of out-of-hospital cardiac arrests (OHCA) is acute coronary artery occlusion. If an immediate coronary angiogram (CAG) is recommended for survivors presenting a ST segment elevation on the electrocardiogram (ECG) performed after resuscitation, there is still a debate regarding the best strategy in patients without ST segment elevation.

Hypothesis

Performing an immediate CAG after an OHCA without ST segment elevation on the post-resuscitation ECG and no obvious non-cardiac cause of arrest could lead to a better 180-day survival rate with no or minimal neurological sequel as compared with a delayed CAG performed 48 to 96 hours after the arrest.

Design

The EMERGE trial is a prospective national, randomized, open and parallel group trial, in which 970 survivors of OHCA will be randomized (1:1) to either immediate (as soon as possible after return of spontaneous circulation) or delayed (48 to 96 h) CAG. Participants will be OHCA patients with no ST segment elevation on the post resuscitation ECG and no obvious non-cardiac cause of arrest. The primary endpoint of the study is the 180-day survival rate with no or minimal neurological sequel corresponding to Cerebral Performance Category (CPC) 1 or 2. The secondary endpoints are: occurrence of shock during the first 48 hours, ventricular tachycardia and/or fibrillation during the first 48 hours, change in left ventricular ejection fraction between baseline and 180 days assessed by echocardiogram, neurological status evaluated by the CPC score at intensive care unit (ICU) discharge and day 90 neurological status assessed by the Glasgow Outcome Scale Extended score (GOSE) at 90 and 180 days, overall survival rate, and hospital length of stay.

Summary

The EMERGE trial is a prospective, multicenter, randomized, controlled trial that will assess the 180-day survival rate with no or minimal neurologic sequel in patients resuscitated from an OHCA without ST segment elevation and who will be managed with either immediate or delayed CAG.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents.
 Take-home message: Design of the EMERGE study which compares an immediate versus a delayed CAG strategy for patients resuscitated after an OHCA without ST elevation and with no obvious non-cardiac cause of arrest.
 RCT# NCT02876458


© 2020  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 222

P. 131-138 - aprile 2020 Ritorno al numero
Articolo precedente Articolo precedente
  • Implementation of Best Practices—Developing and Optimizing Regional Systems of Stroke Care: Design and Methodology
  • Matthew E Ehrlich, Brad J. Kolls, Mayme Roettig, Lisa Monk, Shreyansh Shah, Ying Xian, James G. Jollis, Christopher B. Granger, Carmelo Graffagnino
| Articolo seguente Articolo seguente
  • Distal Evaluation of Functional performance with Intravascular sensors to assess the Narrowing Effect—combined pressure and Doppler FLOW velocity measurements (DEFINE-FLOW) trial: Rationale and trial design
  • Valérie E. Stegehuis, Gilbert W.M. Wijntjens, Tim P. van de Hoef, Lorena Casadonte, Richard L. Kirkeeide, Maria Siebes, Jos A.E. Spaan, K. Lance Gould, Nils P. Johnson, Jan J. Piek

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.